This phase I trial is evaluating the safety and effectiveness of increasing doses of an immunotherapy drug (MK-1308) given in combination with another immunotherapy drug (Pembrolizumab) for the treatment of patients with advanced solid tumours.
This trial is treating patients with Advanced solid tumours.
This is a systemic treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors
Participants eligible for this trial will be assigned to either a Dose Escalation or Dose Confirmation phase of the trial. Patients in the Dose Escalation phase of the trial will receive MK-1308 on Day 1 of the first cycle, MK-1308 and pembrolizumab of Day 1 of cycles 2-5 and pembrolizumab for on Day 1 of the remaining cycles. Patients in the Dose Confirmation phase of the trial will receive MK-1803 and pembrolizumab on Day 1 of all cycles. Patients in both trial phases will be treated for up to 35 cycles.
Recruiting Hospitals Read More